Targeting endothelial permeability in the EPR effect.
Drug delivery
EPR effect
Nanoparticles
Permeability
Tumor
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
13
03
2023
revised:
19
07
2023
accepted:
23
07
2023
medline:
11
9
2023
pubmed:
31
7
2023
entrez:
30
7
2023
Statut:
ppublish
Résumé
The characteristics of the primary tumor blood vessels and the tumor microenvironment drive the enhanced permeability and retention (EPR) effect, which confers an advantage towards enhanced delivery of anti-cancer nanomedicine and has shown beneficial effects in preclinical models. Increased vascular permeability is a landmark feature of the tumor vessels and an important driver of the EPR. The main focus of this review is the endothelial regulation of vascular permeability. We discuss current challenges of targeting vascular permeability towards clinical translation and summarize the structural components and mechanisms of endothelial permeability, the principal mediators and signaling players, the targeted approaches that have been used and their outcomes to date. We also critically discuss the effects of the tumor-infiltrating immune cells, their interplay with the tumor vessels and the impact of immune responses on nanomedicine delivery, the impact of anti-angiogenic and tumor-stroma targeting approaches, and desirable nanoparticle design approaches for greater translational benefit.
Identifiants
pubmed: 37517543
pii: S0168-3659(23)00463-7
doi: 10.1016/j.jconrel.2023.07.039
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
212-235Subventions
Organisme : NCI NIH HHS
ID : R15 CA231339
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103424
Pays : United States
Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.